Reported Earlier, BeiGene Highlights Long-Term BRUKINSA Efficacy And Pipeline Innovations For CLL At ASH 2024
Reported Earlier, BeiGene Highlights Long-Term BRUKINSA Efficacy And Pipeline Innovations For CLL At ASH 2024
早前報道，百濟神州在2024年ASH大會上強調了開多在慢性淋巴細胞白血病中的長期療效和產品線創新。
- 5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitor
- At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-disease option
- Data for BTK degrader BGB-16673 from phase 1/2 study highlight its potential in both treatment-resistant CLL and other B-cell malignancies representing high unmet needs
- SEQUOIA研究的5年跟蹤顯示，與苯達莫司汀-利妥昔單抗相比，BRUKINSA治療可以將治療前未接受治療的慢性淋巴細胞白血病（CLL）患者的疾病進展或死亡風險降低71%，進一步鞏固了其在一線和復發/難治性（R/R）CLL新患者中的領先地位，並且是BTk抑制劑中標籤最廣泛的。
- 在中位隨訪1.5年時，10/10億研究的320 mg擴展隊列的有希望數據顯示，接受sonrotoclax（一種下一代BCL2抑制劑）與BRUKINSA聯合治療的治療前未接受治療的CLL患者沒有疾病進展，突顯了這種固定療程、僅口服的聯合治療作爲最佳疾病治療選擇的潛力。
- 來自1/2期研究的BTk降解劑BGb-16673的數據強調了其在治療耐藥性CLL和其他B細胞惡性腫瘤中的潛力，代表着高未滿足需求。
資訊熱榜
更新時間